Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin has lower sales, higher costs as it ramps up Bydureon sales

This article was originally published in Scrip

Executive Summary

Amylin Pharmaceuticals focused on sales of its once-weekly type 2 diabetes drug Bydureon (exenatide) rather than prospective buyers or investor lawsuits during its first quarter 2012 earnings call during which it reported a revenue decline despite its recent product launch. The company attributed the higher net loss to the cost of ramping up sales for Bydureon, which generated $6.9 million in revenue during its first-ever quarter of sales.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel